Research programme: matrix metalloproteinase inhibitors - Pharmahungary

Drug Profile

Research programme: matrix metalloproteinase inhibitors - Pharmahungary

Alternative Names: MMPharma™ project - Pharmahungary

Latest Information Update: 05 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmahungary Group
  • Class Small molecules
  • Mechanism of Action Matrix metalloproteinase 13 inhibitors; Matrix metalloproteinase 2 inhibitors; Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Myocardial infarction

Most Recent Events

  • 05 Jul 2016 Research programme: matrix metalloproteinase inhibitors - Pharmahungary is available for licensing - http://www.pharmahungary.com/mmp-inhibitors
  • 05 Jul 2016 Early research in Myocardial infarction in Hungary (unspecified rout
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top